- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Roche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreQ&A
December 29, 2010
J.K. WallBruce Frank, a former Roche Diagnostics manager, McKinsey consultant and pro basketball player, talks about
changes in the medical device and life sciences industries.
MoreIndiana Seed Fund makes 11th investment
December 23, 2010
IBJ StaffA $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development
stage.
MoreZimmer looks to China to reignite growth
December 22, 2010
J.K. WallZimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe
are trumping all other factors and keeping the company’s growth bottled up for now.
MoreLilly Endowment gives $35M to start pharmacy school
December 20, 2010
J.K. WallManchester College will use money to launch the state's third program offering doctorates in pharmacy.
MoreBiomet owners look to arrange $11B marriage
December 15, 2010
J.K. WallWarsaw-based Biomet Inc. could get a whole lot bigger if rumors prove true that its owners have made a bid for U.K.-based
rival Smith & Nephew plc.
MoreState adds record number of life sciences jobs
December 11, 2010
IBJ StaffTwenty companies committed this year to add more than 4,000 jobs.
MoreDow AgroSciences moves into new research facility
November 20, 2010
IBJ StaffThe division of Dow Chemical has a 15-year lease with Indianapolis-based developer Browning Investments on the two-story building
near West 96th Street.
MoreMedical device maker expanding in Fort Wayne
November 18, 2010
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its
manufacturing operations.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreAcquisition big step for Lilly Diagnostics
November 10, 2010
J.K. WallEli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s
attempt to add diagnostics to its product portfolio.
MoreDrugmaker restarts race to boost 'good' cholesterol
November 10, 2010
Bloomberg NewsMerck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising
good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreIndiana life sciences upstarts tap health reform booty
November 6, 2010
IBJ StaffThe federal legislation is roundly criticized at a BioCrossroads meeting, but some firms have found a silver lining.
MoreSeeking growth, Lilly dumps Singapore for China
November 3, 2010
J.K. WallAfter recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open
a diabetes research center in China in the second half of 2011, further ramping up the drugmaker's presence in the world's
fastest-growing pharmaceutical market.
MoreLilly to open diabetes research center in China
November 2, 2010
IBJ StaffIndianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing
the high incidence of the disease there.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreBioCrossroads helping laid-off life sciences workers land safely
October 30, 2010
Chris O'MalleyIndiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched
a website that aims to keep that talent in the state.
MoreFormer IU tech-transfer chief: State isn't competitive enough
October 30, 2010
Norm HeikensMark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s
tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
MoreIndiana life sciences sector copes with shrinking VC pool
October 30, 2010
Chris O\'malleyVenture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
MoreDow Agro sales climb, but profit suffers
October 28, 2010
IBJ Staff and Bloomberg NewsIndianapolis-based Dow AgroSciences improved revenue during the third quarter thanks to a 26-percent increase in volume, but
it still recorded a loss for the period.
MoreQ&A
October 20, 2010
J.K. WallAmy Zucker is president of Indianapolis-based Synergy Marketing Group. Her firm was recently hired by Indianapolis-based ImmuneWorks Inc. to use a new website and search engine optimization to help recruit patients for a Phase 1 trial of ImmuneWorks experimental medicine idiopathic pulmonary fibrosis. The Web strategy is a new wrinkle on patient recruitment—in addition to the traditional partnerships with disease specialists at academic medical centers—that Zucker hopes leads to lower costs and faster clinical trials. Phase 1 clinical trials cost nearly $16,000 per patient.
FDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
It's also across the street from Fogo de Chao and Morton's....
Yep, the haters are trying to make good news bad. I guess it is hard to get people to believe the series is dying when they are gaining new sponsors.
David Copperfield! I remember watching his specials on TV when I was little.
Don't forget this is next to an MMA gym, a pawn shop, and some abandoned spaces.
Good project for Zionsville - A group who has owned the property for many years has waited and worked patiently to bring highest and best use development to a major corridor, and mix that in with the great downtown you have. Win Win. All the Best to Pittman Partners and Zionsville.